News

In the experiments, eight Neugene antisense compounds were developed to target regions of the influenza virus genome believed to be critical to virus survival. AVI also selected regions

The approvable letter represents a delay in the drug’s path to market, as it asks for the company to submit more data before it can be approved. However,

The product, 2-methoxyestradiol (2ME2), is currently in clinical trials for cancer and in preclinical development for rheumatoid arthritis. The company also recently gained a US patent covering compositions

Sigma-Aldrich will commercialize the technology for the reagent and research tool market, becoming Oxford BioMedica’s exclusive global partner in the development and marketing of research products based on

The trial is being initiated as a result of a patient recruitment delay faced by Novel 3, one of two ongoing phase III studies of sargramostim in Crohn’s

The proof-of-principle clinical trial in healthy volunteers was intended to test the hypothesis that the compound has potential as a novel medicine for the treatment of insomnia. The

NeurotrophinCell (NtCell) is Living Cell’s injectable live cell product being developed for the treatment of patients with neurodegenerative diseases. NtCell is manufactured using natural porcine cells that are

These ion channels act like electrical wires and permit embryonic stem cells (ESCs), versatile cells that possess the unique ability to become all cell types of the body,

In particular, Generex has announced that the president of Antigen Express, Eric von Hofe, will focus his efforts and those of the company on bringing this new vaccine